Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Molecular PathologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cell fate dynamics and genomic programming of plasma cell precursors.Immunol Rev. 2021; 303: 62-71
- Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow.Immunity. 2015; 43: 132-145
- Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.Blood. 2011; 118: 2702-2707
- Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders.Br J Haematol. 1999; 104: 131-137
- Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group.J Clin Oncol. 2020; 38: 3107-3118
- Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.Nat Commun. 2021; 12: 1861
- Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.Leukemia. 2018; 32: 1044-1048
- Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.Leukemia. 2014; 28: 1725-1735
- Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.Nat Commun. 2019; 10: 1911
- Revealing the impact of structural variants in multiple myeloma.Blood Cancer Discov. 2020; 1: 258-273
- Chromothripsis as a pathogenic driver of multiple myeloma.Semin Cell Dev Biol. 2022; 123: 115-123
- Deciphering the chronology of copy number alterations in multiple myeloma.Blood Cancer J. 2019; 9: 39
- Molecular pathogenesis and a consequent classification of multiple myeloma.J Clin Oncol. 2005; 23: 6333-6338
- Initial genome sequencing and analysis of multiple myeloma.Nature. 2011; 471: 467-472
- Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.Nat Rev Clin Oncol. 2022; : 1-14
- Cereblon enhancer methylation and IMiD resistance in multiple myeloma.Blood. 2021; 138: 1721-1726
- Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.Leukemia. 2021; 35: 887-892
- Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.Nat Commun. 2021; 12: 868
- Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.Nat Med. 2021; 27: 616-619
- Timing the initiation of multiple myeloma.Nat Commun. 2020; 11: 1917
- Reconstructing the evolutionary history of multiple myeloma.Best Pract Res Clin Haematol. 2020; 33: 101145
- The mutagenic impact of melphalan in multiple myeloma.Leukemia. 2021; 35: 2145-2150
- Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma.J Clin Oncol. 2015; 33: 3911-3920
- APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.Nat Commun. 2015; 6: 6997
- Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma.Leukemia. 2020; 34: 1476-1480
- Analytical validation of SKY92 for the identification of high-risk multiple myeloma.J Mol Diagn. 2021; 23: 120-129
- Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.Leukemia. 2014; 28: 1705-1715
- Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.Nat Med. 2018; 24: 1867-1876
- Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.Nat Med. 2021; 27: 491-503
- Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.BMC Med Genomics. 2015; 8: 85
- Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility.Cancer Epidemiol Biomarkers Prev. 2008; 17: 666-673
- Modulation of multidrug-resistant multiple myeloma by cyclosporin.Lancet. 1992; 340: 255-259
- Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization.Nat Cell Biol. 2020; 22: 38-48
- The bone marrow microenvironment at single-cell resolution.Nature. 2019; https://doi.org/10.1038/s41586-019-1104-8
- Three-dimensional map of nonhematopoietic bone and bone-marrow cells and molecules.Nat Biotechnol. 2017; 35: 1202-1210
- Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.Nat Cancer. 2020; 1: 493-506
- Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.Blood. 2021; 138: 330
- The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.Nat Immunol. 2021; 22: 769-780
- Single-cell RNA sequencing: one step closer to the clinic.Nat Med. Published online March. 2021; 4https://doi.org/10.1038/s41591-021-01276-y
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.Nat Commun. 2017; 8: 268
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.Nat Commun. 2022; 13: 4517
- Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.Nat Commun. 2022; 13: 807
- Microscopic examination of spatial transcriptome using Seq-Scope.Cell. 2021; 184: 3559-3572.e22
- Spatial omics and multiplexed imaging to explore cancer biology.Nat Methods. 2021; https://doi.org/10.1038/s41592-021-01203-6
- Multiplex digital spatial profiling of proteins and RNA in fixed tissue.Nat Biotechnol. 2020; 38: 586-599
- The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future.Best Pract Res Clin Haematol. 2020; 33: 101150
- Isatuximab: a review of its use in multiple myeloma.Target Oncol. 2021; 16: 675-686
- Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.Blood Cancer J. 2021; 11: 24
- Detection of plasma cell disorders by mass spectrometry: a comprehensive review of 19,523 cases.Mayo Clin Proc. 2022; 97: 294-307
- Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.N Engl J Med. 2017; 376: 1311-1320
- Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.Leukemia. 2017; https://doi.org/10.1038/leu.2017.35
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.Lancet Oncol. 2021; 22: 142-154
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.Lancet. 2020; 396: 1563-1573
- Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.Leukemia. 2020; 34: 1853-1865
- bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA).Proc Natl Acad Sci U S A. 2020; 117: 5791-5800
- Proteolysis-targeting chimeras as therapeutics and tools for biological discovery.Cell. 2020; 181: 102-114
- Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs.ACS Cent Sci. 2019; 5: 1682-1690
- Advancing targeted protein degradation for cancer therapy.Nat Rev Cancer. 2021; 21: 638-654
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.Lancet. 2021; 398: 314-324
- Idecabtagene vicleucel in relapsed and refractory multiple myeloma.N Engl J Med. 2021; 384: 705-716
- CAR T cell therapies for patients with multiple myeloma.Nat Rev Clin Oncol. 2021; 18: 71-84
- CAR T-cell therapy in multiple myeloma: more room for improvement.Blood Cancer J. 2021; 11: 84
- Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.N Engl J Med. 2019; 381: 727-738
- Mutations and copy number gains of the BCL2 family members mediate resistance to venetoclax in multiple myeloma (MM) patients.Blood. 2019; 134: 572
- Defining the undetectable: the current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.Blood Rev. 2021; 46: 100732
- Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.Pathology. 2021; 53: 385-399
- Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.Br J Haematol. 2020; 189: 904-907
- Mass-fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).Blood Cancer J. 2022; 12: 27
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.Lancet Oncol. 2016; 17: e328-e346
- Minimal residual disease detection by flow cytometry in multiple myeloma: why and how?.Semin Hematol. 2018; 55: 4-12
- Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: feasibility, challenges, and direct comparison with high-sensitivity flow cytometry.J Mol Diagn. 2021; 23: 181-199
- International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.Leukemia. 2021; 35: 18-30
- Minimal residual disease in multiple myeloma: why, when, where.Hematol Am. Soc Hematol Educ Program. 2021; 2021: 37-45
Lohr JG, Kim S, Gould J, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 8:363ra147.
- Tracking myeloma tumor DNA in peripheral blood.Best Pract Res Clin Haematol. 2020; 33: 101146
Article info
Publication history
Published online: September 28, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
